US 5800992

I'll run targeted searches for this exact patent number and check for any 2026 CAFC activity.

I have core bibliographic data. Let me verify claim structure, litigation/reexamination history, and check for any 2026 appellate activity.

Search log and scope note

Searches run against Google Patents, FreePatentsOnline, uspto.report, Espacenet, CourtListener, Unified Patents, and Incyte/Affymetrix SEC filings, targeting the exact string 5800992 / 5,800,992. I filtered out hits for neighboring numbers (5,871,928; 5,744,305; 5,445,934; 6,440,667; etc.), several of which appear in the same family and were surfacing in results. Two queries — the CAFC 2026 docket check and the PTAB check — returned no results at all (see the final section).

Two date caveats before the substance: your prompt says "Current Date: April 26, 2026," the session date given to me is 2026-09-10, and the authoritative full text I was handed was fetched 2026-09-08. I'll treat "2026" as the operative year.

1. Identification

2. Priority chain (material to the effective filing date)

The 1996-06-25 filing date is the actual filing date; the effective filing date traces back much further:

• 07/362,901 — filed 1989-06-07 (earliest)
• 07/492,462 — filed 1990-03-07; issued as US 5,143,854
• 07/624,114 — filed 1990-12-06 (continuation-in-part)
• 08/168,904 — filed 1993-12-15 (continuation of '114), abandoned
• 08/670,118 — filed 1996-06-25, i.e. a division of the abandoned 08/168,904 → issued as 5,800,992

Continuations/divisions off 08/670,118 include US 5,871,928, 5,925,525, 6,197,506, 6,440,667, 6,395,491, 6,355,432, 6,541,739, 6,610,482, 6,379,895, 6,416,952, 6,451,536, 6,403,320, 6,576,424, 6,551,784 and 6,919,211. This is why the same specification recurs across so many Affymetrix patents.

3. Abstract (verbatim, per Espacenet bibliographic record)

"The present invention provides method and apparatus for sequencing, fingerprinting and mapping biological macromolecules, typically biological polymers. The methods make use of a plurality of sequence specific recognition reagents which can also be used for classification of biological samples, and to characterize their sources."

Worth flagging: the abstract is far broader than the claims. The claims are not directed to sequencing or mapping at all — they are directed to detecting nucleic acids in collections and to differential gene expression.

4. Plain-language overview of the independent claims

Claim text below is as retrieved from FreePatentsOnline (a secondary source — I did not pull the USPTO full-text claims feed directly, so treat wording as high-confidence but not primary-verified).

Independent Claim 1 — simultaneous two-color detection on an array.
You provide an array of polynucleotides fixed to a solid surface. You then contact that array with two or more collections of labelled nucleic acid, where each collection is substantially complementary to something on the array, and the labels are distinguishable from one another. Then you detect where each labelled collection hybridized. In plain terms: hybridize two differently-tagged samples to one chip at the same time and read both signals at once — the core two-color microarray experiment. Dependent claim 2 limits the solid support to an array of beads; claim 3 limits the labels to fluorescent labels.

Independent Claim 4 — differential gene expression between two cell types.
You label nucleic acid from two cell types, mix them, and apply the mixture to an array of polynucleotides representing known genes from those cell types, under hybridizing conditions. You then read the array by fluorescence under excitation conditions chosen so that hybridization from cell type A gives one emission color and hybridization from cell type B gives a different emission color — the ratio of the two colors reports the differential expression of each gene. Dependent claim 5 adds the density/element-size limitation: the array is on a substrate bearing "at least 10³ distinct polynucleotide[s] in a surface area of about 1 cm²," each at a separate defined position.

Caveat on claim 5's wording: the source text renders this as "at least 103 distinct polynucleotide in a surface area of about 1 cm2." Read literally that is the number one hundred three; the scientific context (and the parallel density language in sibling patents such as the '305 patent, described in Affymetrix v. Hyseq as "greater than 400 different oligonucleotides … per square centimeter") strongly indicates a lost superscript, i.e. 10³. I am reporting the literal string and the likely true reading rather than silently correcting.

5. Legal status and the most important thing to know: the claims were invalidated

This is the item most summaries omit. Per Incyte Genomics' own December 9, 2002 SEC disclosure:

• In Incyte Pharmaceuticals, Inc., et al. v. Affymetrix, Inc., Case No. C99-21111 JF (N.D. Cal.), a final judgment was entered by Judge Fogel on December 4, 2002 providing that "claims one through five" of US 5,800,992 are invalid, so that no interference could exist between those claims and claims of US Application 08/514,875 (licensed from Stanford).
• That judgment was part of a December 2, 2002 settlement among Incyte, Affymetrix and the Leland Stanford Junior University, which also resolved Interferences 104,358 and 104,359, an EPO opposition (EP 1 080 473 B1) and an Australian opposition (AU 709276).
• This followed the December 21, 2001 global settlement of the infringement actions, which had cross-licensed the portfolios and expressly covered 5,445,934, 5,744,305, 5,800,992, 5,871,928 and 6,040,193.
• Context for how the claims got there: in the 1999–2001 N.D. Cal. / D. Del. litigation, the court's January 2001 Markman ruling on "substantially complementary" was read by Incyte as narrowing the claims outside its arrays; Affymetrix, Inc. v. Hyseq, Inc. confirms that Affymetrix asserted claims 1 and 4 (the independents) plus 3 and 5 of the '992 patent, and that claims 1–3 of a related patent were held invalid on partial summary judgment.

So: the "Expired – Fee Related" status line and the 2009-06-07 anticipated expiration on Google Patents do not mean the patent lived out its full term as a valid, enforceable right. All five claims were adjudged invalid in 2002. I have not verified whether that 2002 final judgment was appealed, and if appealed whether it was affirmed or vacated — I'd treat that as an open question requiring PACER/CAFC docket review.

Chain of title, as recorded, is also non-trivial: a 1999-02-08 merger assignment (Affymetrix, California → Affymetrix, Delaware) and a 2000-07-03 assignment from Fodor/Solas/Dower to Affymax Technologies N.V. plus Affymax → Affymetrix. That explains why the printed front page and the post-2000 assignment records name different entities.

6. CAFC 2026 docket check — result: nothing found

I ran targeted searches for Federal Circuit 2026 appellate activity involving 5,800,992 (including a direct "patent 5800992 appeal" query and a PTAB query). Both returned zero results. I must be explicit about the limits of that finding:

• I did not query PACER/CM-ECF or the CAFC's own docket system directly; I only have open-web access. Absence of search results is not evidence of absence of a docket.
• Given that (a) all five claims were held invalid in December 2002, (b) the patent's anticipated expiration is 2009-06-07, and (c) the last related litigation settled by December 2002, there is no affirmative basis in anything I retrieved for a live 2026 appeal involving this number. If you need certainty, this must be confirmed against the CAFC docket directly.

7. Confidence and uncertainty flags

• High confidence: patent number, title, inventors, application number, filing date, issue date, priority date, claim count (5), independent claims (1 and 4), the abstract text, the 2002 invalidity judgment, the two settlements, and the priority chain.
• Medium confidence: the verbatim claim language (secondary source), and the "10³" reading of claim 5.
• Uncertain / not verified: whether the 2002 invalidity judgment was appealed or modified; the precise reason for the "Expired – Fee Related" status label; the identity of the assignee as printed on the face of the granted patent versus as recorded post-1999; and any 2026 docket activity.

I'll search for litigation involving US patent 5800992 across patent litigation databases.

Let me dig deeper into specific litigation databases and the Affymetrix litigation history.

Let me search for specific case numbers and outcomes.

Litigation involving US Patent No. 5,800,992 ("Method of detecting nucleic acids")

Important note on search limitations: I was able to confirm that this patent was asserted in the Affymetrix microarray patent campaign of the late 1990s, but I hit my tool-call limit before I could verify docket numbers for one of the two cases. I have flagged below exactly what I could and could not confirm. I did not find any dedicated Unified Patents litigation record for this patent number (the portal search returned nothing on-point), and I found no litigation outside the Affymetrix v. Incyte/Synteni and Affymetrix v. Hyseq matters.

1. Affymetrix, Inc. v. Synteni, Inc. and Incyte Pharmaceuticals, Inc. (later Incyte Genomics, Inc.)

Sources: CourtListener, Affymetrix, Inc. v. Synteni, Inc. (https://www.courtlistener.com/opinion/[2531759](/patent/2531759)/affymetrix-inc-v-synteni-inc/); Incyte legal-proceedings disclosures (https://investor.incyte.com/node/8156/html); Incyte press release, Dec. 21, 2001, "Affymetrix and Incyte Genomics Settle All Patent Infringement Litigation" (https://investor.incyte.com/node/21246/pdf); Affymetrix 10-Q (Q3 2001) via CapEdge (https://capedge.com/filing/[913077](/patent/913077)/0000912057-01-[539101](/patent/539101)/AFFX-10Q-2001Q3); BioCentury, "Markman ruling on arrays," Jan. 25, 2001 (https://www.biocentury.com/article/22987/markman-ruling-on-arrays).

2. Affymetrix, Inc. v. Hyseq, Inc.

Sources: CourtListener, Affymetrix, Inc. v. Hyseq, Inc. (https://www.courtlistener.com/opinion/[2457323](/patent/2457323)/affymetrix-inc-v-hyseq-inc/); Affymetrix, Inc. v. Synteni, Inc. transfer opinion (https://www.courtlistener.com/opinion/2531759/affymetrix-inc-v-synteni-inc/).

Related (non-litigation) proceedings — flagged for completeness

In April 1999 the Board of Patent Appeals and Interferences of the USPTO declared interferences between pending patent applications licensed exclusively to Incyte and the Affymetrix '305 patent. These are administrative interference proceedings, not court litigation, and I did not find an interference specifically directed to the '992 patent.

What I did not find

• No litigation naming US 5,800,992 outside the two Affymetrix campaigns above (no NPE, no ITC § 337 action, no later district-court assertion).
• No CAFC appeal decision specifically addressing the '992 patent in the sources I retrieved (the 2001 invalidity/non-infringement rulings were overtaken by the December 2001 settlement).
• A Unified Patents portal record for this patent number (search returned no on-point litigation page).

Caveats: Per your instruction I have not auto-corrected any patent numbers — US 5,800,992 is the number searched, and the search results conflate it with sibling patents (5,445,934; 5,744,305; 5,795,716; 5,871,928; 6,040,193) that were asserted in the same family litigation. The case number for the Synteni/Incyte action and the final disposition of the Hyseq action remain unverified; if you need those pinned down, the next step would be a PACER/N.D. Cal. docket lookup and a check of the Darts-ip family-litigation record linked from the Google Patents page (https://patents.darts-ip.com/?family=27496811).

I'll verify the ODP's "no proceedings" result against public sources before drafting.

Let me confirm the absence with targeted PTAB-focused searches.

Two more checks: any Federal Circuit appeal touching the '992, and the exact terms of the 2002 invalidity judgment.

Proceedings overview

Zero AIA trial proceedings on file. The USPTO ODP structured block reports no IPR, PGR, or CBM for US 5,800,992, and my independent searches (Google Patents family view, PTAB-focused queries, litigation-history searches) surfaced no petition, institution decision, or FWD against this patent. Breakdown: 0 active / 0 claims invalidated by the PTAB / 0 claims sustained by the PTAB / 0 settled / 0 institution denied. Critically, the absence of PTAB activity is not a signal that the patent is hardened — the opposite is true. US 5,800,992 was held invalid in its entirety by a federal district court in 2002, and its term expired 2009-06-07 (Google Patents, US5800992A), roughly three years before the PTAB accepted its first IPR petition on 2012-09-16. There was never a patent left to challenge at the PTAB. A defendant's defensive posture is therefore "the patent is already dead by Article III judgment and by expiration," not "the PTAB cleared it."

Confidence note: the "no AIA proceedings" finding rests on the ODP block plus search coverage that was not exhaustive. I did not retrieve a PTAB E2E docket for the patent directly — if you need belt-and-suspenders confirmation, run the patent number in PTAB E2E before relying on the negative.

The operative proceeding was not an AIA trial — it was a district court invalidity judgment

AIA-trial section headings are omitted below because there are no proceeding numbers to cite; inventing one would violate the "do not fabricate" constraint. The record that matters to a defendant is this one:

N.D. Cal. Case No. C 99-21111 JF — Incyte Pharmaceuticals, Inc., et al. v. Affymetrix, Inc. (the '992 invalidity judgment)

• Type: District court patent litigation; not an IPR / PGR / CBM.
• Filed: Case number C 99-21111 JF (N.D. Cal.), cited in Incyte's 2002-12-02 SEC disclosure; the underlying Affymetrix enforcement campaign began with the 1998 Delaware/N.D. Cal. suits (Affymetrix v. Synteni; Affymetrix v. Hyseq, N.D. Cal. Case No. C 98-03192).
• Status: Final judgment entered 2002-12-04 by Judge Fogel holding claims 1–5 of US 5,800,992 invalid. Incyte's filing states verbatim that the judgment "provides, in part, that claims one through five of Affymetrix's United States Patent No. 5,800,992 (the '992 Patent') are invalid and that, therefore, there can be no interference between such '992 Patent claims and certain claims of United States Patent Application No. 08/514,875." (Incyte SEC filing, 2002-12-02)
• Judge panel: Hon. Jeremy Fogel (N.D. Cal.). No APJ panel exists — this was not a Board proceeding.
• Grounds: § 112, not § 102/§ 103. Secondary reporting on the Japanese/Chinese patent-strategy literature states claims 1–3 fell for indefiniteness and claims 4–5 for failure of written description. Treat that claim-by-claim allocation as unverified secondary-source reporting; the primary document I retrieved (the Incyte filing) confirms only that "claims one through five" were held invalid.
• Institution decision: N/A. The vehicle was summary judgment, not institution.
• Claim-level verdict: All five claims invalid — claims 1–5. The patent has two independent claims, 1 and 4, with claims 2, 3, and 5 dependent (Affymetrix, Inc. v. Hyseq, Inc., CourtListener: "Affymetrix accuses Hyseq of infringing claims 1 and 3 of the '992 patent, and Incyte of infringing claims 1, 3, 4, and 5. Claims 1 and 4 are independent claims."). So both independent claims are dead — there is no surviving independent claim to build any infringement theory on.
• Settlement / termination: The judgment was entered as part of a global 2002-12-02 settlement resolving Incyte Pharm. v. Affymetrix (C 99-21111 JF), Patent Interference Nos. 104,358 and 104,359 (involving Stanford's Brown et al. '875 application), the Affymetrix opposition to EP 10804731, and the Affymetrix opposition to AU 709276. Terms beyond this are confidential; the litigation was resolved alongside the earlier 2001-12-21 global settlement of the parties' infringement suits over US 5,445,934, 5,744,305, 5,800,992, 5,871,928, and 6,040,193, which included cross-licenses and undisclosed financial terms (Incyte press release, 2001-12-21).
• Appeal: None on record. Secondary reporting indicates the patent owner gave up its right to appeal as part of the settlement, which is why the invalidity judgment stands unchallenged. I could not verify a Federal Circuit docket number because there was apparently no appeal — do not cite a CAFC docket for this judgment without pulling the N.D. Cal. docket first.
• Defensive value: Near-total. Every claim of the asserted patent has been adjudged invalid, and that judgment is now beyond appeal. Any 2026 demand letter asserting claims 1–5 of US 5,800,992 is asserting claims that a district court has already declared invalid — a Rule 11 / § 285 exposure, not a licensing opportunity.

Strategic summary

Claim status: all five claims invalid; none survive. Claims 1, 2, 3, 4, and 5 of US 5,800,992 were all held invalid by final judgment on 2002-12-04. There is no narrowed-but-surviving claim set. Separately, the patent's term ended 2009-06-07 ("Anticipated expiration," Google Patents), reflecting a 20-year term from the 1989-06-07 priority date, and its legal status is listed as Expired – Fee Related. Untested claims: none. Notably, the patent's own litigation history is entirely pre-PTAB: Affymetrix asserted it against Hyseq (claims 1 and 3) and Incyte (claims 1, 3, 4, and 5) in 1998–1999, and the January 2001 Markman ruling in that campaign was reported to have construed the array patents narrowly enough that defendants' products fell outside their scope (BioCentury, 2001-01-25).

Estoppel landscape. There is no § 315(e)(2) estoppel to analyze, because no IPR was ever instituted — no petitioner exists, and no petitioner's privies are barred. The flip side is that no IPR-estoppel shield is needed: the invalidity defense here is judgment-based, not estoppel-based. Under Blonder-Tongue v. University of Illinois Foundation, a final judgment of invalidity against a patentee ordinarily bars the patentee from relitigating validity against a new defendant, and an invalid patent cannot support an infringement action at all. Caveat for counsel: pull the actual judgment order from the N.D. Cal. docket (C 99-21111 JF) to confirm whether it was entered as an adjudicated summary-judgment disposition or wrapped into a stipulated consent judgment, since that distinction affects how cleanly preclusion and § 282 presuit defenses apply. Any prior-art grounds you might otherwise have asserted (e.g., § 102/§ 103 over the 1980s–1990s array literature) remain formally unadjudicated by the PTAB — but they are irrelevant for practical purposes, because there is no live claim to invalidate and no live term to infringe.

Pattern signals. The same patent owner (Affymetrix) pursued an aggressive multi-front enforcement campaign in the 1998–2002 window against Incyte, Synteni, and Hyseq, and every thread terminated in settlement or judgment — none reached a Federal Circuit validity merits disposition that I could verify. No defensive aggregator (Unified Patents, RPX, etc.) appears anywhere in the chain; such entities did not exist at the relevant time and had no patent to challenge after 2002. There is no serial-petitioner pattern and no PTAB appellate pattern, because the PTAB did not exist during this patent's enforceable life. Google Patents does flag the family as having litigation (Darts-IP family 27496811), which reflects the 1998–2002 suits — not AIA trials.

Recommended next steps

1. If you hold a demand letter citing US 5,800,992: respond on two independent grounds. (a) Invalidity judgment — order the certified copy of the 2002-12-04 final judgment in Incyte Pharmaceuticals, Inc. v. Affymetrix, Inc., N.D. Cal. Case No. C 99-21111 JF, and quote its operative language: "claims one through five of Affymetrix's United States Patent No. 5,800,992 ... are invalid." (b) Expiration — the patent expired 2009-06-07, so there is no post-2009 conduct that can infringe, and § 286's six-year damages lookback would in any event reach only conduct on or before 2009-06-07.
2. Preserve the evidence now. The Incyte SEC filing (2002-12-02) and press release (2001-12-21) are stable public links, but the judgment order itself should be obtained from PACER/the N.D. Cal. docket. Secondary sources confirm the all-claims disposition; the primary court document is what you actually put in a letter.
3. Do not frame your defense as an IPR story. There is no IPR to cite, no FWD to link, and no institution decision to distinguish. Saying "no IPR was ever filed" accurately describes the record but would be misleading if it implies the patent survived scrutiny — it did not. Lead with the 2002 judgment and the 2009 expiration.
4. If you nonetheless need PTAB confirmation: run the patent number through PTAB E2E and the USPTO Patent Center (links on the Google Patents page). My search did not exhaustively query the E2E docket, so "no PTAB activity" is a high-confidence but not independently docket-verified conclusion.
5. Flag any conflicting filing to me. If a search of E2E or a third-party aggregator surfaces an IPR/PGR/CBM number for the '992, that would contradict this analysis (the patent expired in 2009 and predates CBM-eligible subject matter, so such a filing would be anomalous and worth investigating before you rely on anything here).

I'll try to pull the recorded assignment data before writing anything up.

Ownership and Assignment Analysis — US 5,800,992

Source-access caveat, stated up front. I was not able to query the USPTO Patent Assignment Search / Assignment Center directly in this session (no live database connection to assignmentcenter.uspto.gov / assignment.uspto.gov). The web searches I ran returned documentation about the Assignment Center (Finnegan, IAM, USPTO webinar deck) and third-party descriptions of its fields — not the record set for this patent. Consequently:

• I cannot supply reel/frame numbers and will not invent them. The reel/frame fields below are marked [UNVERIFIED — retrieve at source].
• I cannot supply the recorded correspondents of record. Inventing an attorney name here would be the single most damaging error possible in an NPE-chain analysis, so that field is marked [NOT RETRIEVED].
• The assignment events below are taken from the Google Patents legal-events mirror of USPTO recordation data in the authoritative patent text supplied to me, which does give conveyance type, assignor, assignee, and recordation date, but not reel/frame or correspondent.
• Verification queries to run: https://assignment.uspto.gov/patent/index.html (search property 5800992) and https://patents.google.com/patent/US5800992/en#legalEvents.

Inventors

Unusual-pattern note (important, and it cuts the other way from a fire-sale tell). All three inventors signed assignments running to Affymax Technologies N.V., not to Affymetrix, and the entire inventor team later surfaced at Affymetrix. This looks like the "all inventors leave the original assignee" pattern on its face — but it is a corporate spin-out, not a departure: Affymetrix was formed out of the Affymax organization in the early 1990s, and the inventors moved as part of that reorganization while the patent rights were papered over to Affymetrix (see 2000-07-03 entries below). Treating the inventor movement as attrition evidence would be a misread.

Related-inventory note: the '992 patent is one of a family ("all three derive from the originally filed U.S. Patent Application No. 362,901," per Affymetrix, Inc. v. Hyseq, Inc.), siblings including US 5,445,934 and US 5,744,305 — the latter the core GeneChip patent. Inventorship of claims 4–5 of '992 was contested by Incyte/Stanford in Patent Interference No. 104,358 (Brown et al. v. Fodor et al.), which is why the assignment chain mattered to the litigation.

Original assignee

Affymetrix, Inc. (Santa Clara, California), named on the face of the issued patent; the family's original assignee of record in the underlying chain was Affymax Technologies N.V.

• Primary line of business: commercial DNA microarray / "GeneChip" systems for gene-expression monitoring, genotyping and polymorphism analysis — i.e. an operating company, not a licensing vehicle.
• Did they ship a product embodying the claims? Yes. The '992 claims cover two-color differential gene-expression detection on an array (claims 1–3) and differential expression across two cell types (claims 4–5) — as described in Affymetrix v. Hyseq. Affymetrix's GeneChip platform was the accused-and-practiced product; the company's own 1999 S-3/10-Q filings state it "will need to be successful in asserting Affymetrix patents in the DNA array field" to protect GeneChip pricing and margins.
• Current status: Affymetrix operated independently (NASDAQ: AFFX) until 31 March 2016, when Thermo Fisher Scientific Inc. (NYSE: TMO) completed its acquisition of Affymetrix for ~$1.3 billion ($14.00/share cash) following a competing, ultimately withdrawn bid by Origin Technologies. Affymetrix stock ceased trading. Affymax N.V./Affymax Technologies N.V., the earlier holder in this chain, is a separate, long-defunct-era entity (Affymax N.V. was a Netherlands-incorporated Affymax/Glaxo joint venture vehicle); I do not have a verified dissolution record for it and will not assert one.

Assignment timeline

All dates below are recordation dates as mirrored by Google Patents legal events; execution dates are not exposed by that mirror and are not fabricated here.

• 1999-02-08 (recorded) — Reel [UNVERIFIED]/[UNVERIFIED]

  • Conveyance: Merger (see document for details)
  • Assignor: AFFYMETRIX, INC., A CALIFORNIA CORPORATION
  • Assignee: AFFYMETRIX, INC., A DELAWARE CORPORATION
  • Correspondent: [NOT RETRIEVED]
  • Context: internal reorganization only — the Delaware reincorporation. Affymetrix's shareholders voted to reincorporate in Delaware in June 1998 and completed it in late September 1998 (Affymetrix v. Synteni, N.D. Cal. transfer opinion, which notes the company claimed the move was "for reasons unrelated to this lawsuit" while the court nonetheless treated Affymetrix as a foreign corporation for §1404(a) purposes); the merger deed was then recorded at USPTO on 1999-02-08. No change in beneficial ownership.

• 2000-07-03 (recorded) — Reel [UNVERIFIED]/[UNVERIFIED]

  • Conveyance: Assignment of Assignors' Interest (see document for details)
  • Assignor: DOWER, WILLIAM J.; FODOR, STEPHEN P.A.; SOLAS, DENNIS W.
  • Assignee: AFFYMAX TECHNOLOGIES N.V.
  • Correspondent: [NOT RETRIEVED]
  • Context: original inventor-to-employer assignment (late-recorded). This is the first link in the chain in substance, even though it appears at USPTO under a 2000 recordation date — a classic late-recordation artifact for early-1990s biotech paperwork.

• 2000-07-03 (recorded) — Reel [UNVERIFIED]/[UNVERIFIED]

  • Conveyance: Assignment of Assignors' Interest (see document for details)
  • Assignor: AFFYMAX TECHNOLOGIES N.V.
  • Assignee: AFFYMETRIX INC.
  • Correspondent: [NOT RETRIEVED]
  • Context: spin-out clean-up / internal chain-of-title perfection — Affymax Technologies N.V. papered the family over to Affymetrix, completing the title that the 1998 merger and the 1998–2000 litigation had made urgent. Recorded in the same batch as the inventor assignment above, which is why both carry the 2000-07-03 date.

• No further recorded assignment mirrors on this patent. In particular, no Thermo Fisher Scientific assignment or merger recordation surfaces for US 5,800,992, notwithstanding the March 2016 merger. Given the patent's term ended 2009-06-07 and Google Patents carries it as "Expired – Fee Related," it is likely that the 2016 merger recordation (if filed at all) did not enumerate an already-expired asset. I flag that as unverified rather than as a finding.

If the Assignment Center returns nothing beyond the three entries above, that is consistent with the Google Patents mirror and would confirm the chain described here. My searches did not disclose any additional conveyances, and I have not found evidence of a chain running to any licensing entity.

Timeline diagram

timeline
    title Ownership of US 5800992
    1989 : Inventors file parent application 362901
    1996 : Continuation filed as 08670118
    1998 : Patent issues Sept 1
         : Affymetrix sues Hyseq and Incyte on 992
         : Affymetrix completes Delaware reincorporation
    1999 : California to Delaware merger recorded
    2000 : Inventor to Affymax Technologies deed recorded
         : Affymax Technologies to Affymetrix deed recorded
         : Court denies preliminary injunction
    2002 : Final judgment holds claims 1 to 5 invalid
    2009 : Patent term ends
    2016 : Affymetrix acquired by Thermo Fisher

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. No "IP / Holdings / Licensing / Ventures" assignee appears anywhere in the chain. The only two assignees are Affymax Technologies N.V. (a research-stage biopharma affiliate) and Affymetrix, Inc. (Delaware), both operating entities. No Delaware or Texas single-purpose LLC appears at any reel in this chain.

2. Known asserter in the chain — NOT PRESENT. No link to Acacia, Marathon, Intellectual Ventures, IPNav, Wi-LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio IP Ventures, MPHJ, Lumen View, Round Rock, Document Generation Corp, or any Spangenberg-affiliated entity. The only entity that asserted this patent was Affymetrix itself — and it asserted it against direct microarray competitors Hyseq (N.D. Cal. C 98-03192, '992 added by amendment 1998-09-01) and Incyte/Synteni (D. Del., later transferred to N.D. Cal., '992 added 1998-09-01). That is competitor-versus-competitor assertion, not NPE monetization.

3. Repeat correspondent across the chain — UNRESOLVED / NOT ASSESSABLE. This is the one signal I genuinely cannot close out: the correspondent of record is not exposed in any source available to me. Note that the two 2000-07-03 recordations were filed in the same batch for the same assignee, which normally implies a single correspondent handling both. Retrieving that name from the Assignment Center is the highest-value remaining step, but proceeding without it is mandatory here — a one- or two-appearance correspondent in a single-family clean-up is not evidence of anything.

4. Cascading transfers — NOT PRESENT. Two substantive links (inventors → Affymax Technologies N.V.; Affymax Technologies N.V. → Affymetrix) plus one intra-corporate merger. No chained LLCs, no common-principal relays, no shared registered-agent address appearing as an assignee.

5. Pre-litigation transfer — NOT PRESENT / INVERSE of the pattern. The patent issued 1998-09-01, and the same day Affymetrix amended both complaints to add the '992 patent. There is no assignment timed to precede suit, because no assignment was needed: Affymetrix already held title and sued as the operating patentee. The 1998 reincorporation predates the suits by months and is explicitly characterized in the court record as unrelated.

6. Bankruptcy fire-sale — NOT PRESENT. No Chapter 7/11 assignee or trustee appears. Affymetrix's transition was a $1.3 billion cash merger into Thermo Fisher on 2016-03-31, not a distressed sale — and it post-dates the patent's 2009-06-07 term expiry by seven years.

7. Privateering — NOT PRESENT. Affymetrix sued on its own behalf (Hyseq, Incyte/Synteni) and separately litigated against NPE-style threats (Applera, OGT). No transfer of this patent to a proxy asserter is recorded.

8. Defensive aggregator (anti-NPE) — NOT PRESENT. No RPX, AST, LOT Network, Unified Patents or OIN recordation for this patent. The asset was neutralized by other means (see Verdict).

Additional signal worth recording because it disposes of the asset entirely: on 2002-12-04, Judge Fogel entered final judgment in Incyte Pharmaceuticals, Inc., et al. v. Affymetrix, Inc., No. C99-21111 JF (N.D. Cal.) holding claims 1 through 5 of US 5,800,992 invalid (reported in Incyte's 2002-12-02 SEC filing). The earlier decision of Judge Fern M. Smith had already denied Affymetrix's preliminary injunction on the '992 patent (May 2000), finding "a substantial question regarding the validity of relevant portions of the '992 patent." The 2001-12-21 Affymetrix–Incyte settlement cross-licensed the portfolios. A patent judicially invalidated in 2002 and expired in 2009 has essentially zero monetization value and, predictably, was never transferred to an NPE.

Verdict

Operating-company assertion.

The chain on the USPTO mirror runs Fodor/Solas/Dower → Affymax Technologies N.V. (recorded 2000-07-03) → Affymetrix, Inc. (recorded 2000-07-03), preceded only by the intra-corporate Affymetrix California → Affymetrix Delaware merger recorded 1999-02-08. No licensing entity, asserter, aggregator or shell LLC appears at any point, and the patentee was the entity that enforced the patent — Affymetrix added the '992 patent to its suits against Hyseq (1998-09-01 amendment, C 98-03192 N.D. Cal.) and Incyte/Synteni (1998-09-01 amendment) while selling the accused-and-practicing GeneChip product line. The patent was then held invalid as to claims 1–5 by final judgment on 2002-12-04 and its term ended 2009-06-07, so this is a historically operating-company assertion rather than a live one — which is precisely why no subsequent transfer appears.

Residual uncertainty (please close before relying on this): reel/frame numbers and recorded correspondents for all three entries are unverified, because I could not reach the USPTO Assignment Center in this session. Verify at https://assignment.uspto.gov/patent/index.html (property number 5800992) and cross-check https://patents.google.com/patent/US5800992/en#legalEvents. If a correspondent name recurs on the two 2000-07-03 entries, note it — but on this record it would still be a single-family clean-up filing, not an NPE signal.

I'll research this systematically, starting with the patent record itself and then its cited prior art.

Let me pull the front-page references cited from multiple patent databases.

I have the cited-references list. Now let me get the actual claims of the patent and the remaining references.

0. Record verification (only US 5,800,992 — no sibling substitutions)

US 5,800,992 B1 — "Method of detecting nucleic acids"

Sources used and their exact URLs:

• Google Patents record for this number: https://patents.google.com/patent/US5800992/en (this is also the authority text supplied to me)
• FreePatentsOnline record (mirrors the USPTO front page, including the "US Patent References" and "Foreign References" lists quoted in §3): https://www.freepatentsonline.com/5800992.html
• Espacenet bibliographic record (priority chain): https://pt.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=22&ND=8&adjacent=true&locale=pt_pt&FT=D&date=19980901&CC=US&NR=[5800992A](/patent/5800992A)&KC=A
• Claim-content descriptions: Affymetrix, Inc. v. Hyseq, Inc., https://www.courtlistener.com/opinion/[2457323](/patent/2457323)/affymetrix-inc-v-hyseq-inc/ (also mirrored at vLex and Casetext)
• Continuity data (division/continuation chain): USPTO Official Gazette text of US 6,440,667 / 6,395,491 / 6,355,432 as re-published at https://webapp1.dlib.indiana.edu/virtual_disk_library/index.cgi/[5628977](/patent/5628977)/FID2/og/html/1261-4/us06440667-20020827.html

Search result to be careful about: my queries repeatedly returned the sibling numbers 5,445,934; 5,744,305; 5,795,716; 5,871,928; 6,040,193; 6,190,751; 6,440,667; 6,395,491; 6,355,432; 6,616,482; 6,544,739; 6,582,908; 6,579,642; 6,571,788(?)/6,576,424. Those are family members that share the specification lineage, not US 5,800,992. Everything below is keyed to 5,800,992 only.

1. Explicit gap in the authoritative text (flagged, not papered over)

The "full patent text" supplied for US5800992 contains the bibliographic/INPADOC/classification data and the abstract, but it does not contain (a) the claims, or (b) the front-page "References Cited" list. The cited-references list in §3 below therefore comes from the FreePatentsOnline front-page transcription (USPTO-derived), not from the supplied text. This matters because §102 anticipation is claim-element-by-element, and I could not retrieve verbatim claim language from any source within my budget. The claim descriptions I rely on are the court's paraphrase in Affymetrix v. Hyseq (claims 1 and 3 asserted against Hyseq; claims 1, 3, 4, 5 against Incyte; claims 1 and 4 are the independents). Treat all claim mapping below as provisional pending verbatim claim text.

(Note also the contradiction already logged in the earlier litigation section: the May 2001 rulings invalidated/limited the '992 on §112 indefiniteness ("substantially complementary"), not on §102 anticipation — which is consistent with what I find below.)

2. Critical dates that govern any §102 analysis

Continuity chain (verified from the Official Gazette text of the child patents and the Espacenet priority list):

Consequences:

• Claims supported only by matter added in the CIPs (the two-color/differential-expression subject matter, per the Hyseq and Synteni/Incyte opinions, where the three patents' specifications "differ in many respects") get the later effective dates — 1990-12-06, 1993-12-15 or 1996-06-25 — not 1989-06-07.
• §102(b) critical dates therefore range from 1988-06-07 (if 1989-06-07 controls) up to 1995-06-25 (if only 1996-06-25 controls). This is the single biggest variable in whether the cited references are anticipatory art or merely §103 art.
• §102(a) throws in everything published before the invention date (unsworn; assume ~mid-1989 at the earliest).
• §102(e) applies only to references "by another" — which excludes the patent's own family members (see US 5,445,934 and US 5,143,854 below).

3. References cited on the face of US 5,800,992

U.S. Patent Documents (issue dates as listed; filing dates flagged as unverified where I could not confirm them):

Foreign Patent Documents (dates are publication dates as listed by FPO):

"Other References" (NPL): not retrievable in this session. The Google Patents page for this number surfaces only the keyword set "sequence / substrate / sequences / specific / reagents." I will not invent an NPL list.

4. Reference-by-reference §102 assessment

Governing caution: anticipation under §102 requires a single reference disclosing every claim element. Claim 1 (per the court's description) requires (i) an array of polynucleotides on a substrate, (ii) two collections of labeled nucleic acids, (iii) two labels distinguishable from each other, (iv) contacting the array, and (v) detecting hybridization simultaneously. Claim 4 requires differential gene-expression comparison between two cell types using distinct fluorescent labels. On the material retrieved, no cited reference discloses element (iii) in combination with (i)–(v), so my conclusion is that none of the cited references fully anticipates claims 1 or 4; several anticipate or come very close to narrower sub-combinations (arrays; SBH readout; solid-phase hybridization; labeling chemistry), i.e., they are §103 material as much as §102 material.

Tier 1 — most relevant prior art

WO 89/10977 A1 (1989-11-16), "Analysing polynucleotide sequences"

• Citation: PCT publication, publ. 1989-11-16 (Southern-type array hybridization disclosure; the reference behind the later Oxford Gene Technology/Affymetrix dispute over array patents).
• Disclosure: hybridization of polynucleotides to a spatially ordered array of oligonucleotides/KNOWN sequences immobilized on a support to analyse unknown polynucleotide sequences.
• §102 posture: Not §102(b) if the 1989-06-07 parent date controls for the relevant claim (published after that date). Becomes §102(a) art only for claims invented after 1989-11-16, and §102(e) art (as a PCT designating the US, as of its international filing date) only for claims whose effective date post-dates that filing.
• Claims potentially anticipated: any claim limited to "contacting a polynucleotide with an array of sequence-specific polynucleotides on a substrate and detecting hybridization." Not claims 1/4 as described (no two distinguishable labels; no differential-expression readout in the retrieved description).
• Confidence: high on the document and its relevance category; medium on the element-by-element gap (I did not read the document's full text this session).

US 5,202,231 (1993-04-13), US 5,492,806 (1996-02-20), US 5,525,464 (1996-06-11) — Drmanac et al. (SBH family)

• Disclosure: sequencing by hybridization — hybridize labeled target/pool to a defined array of oligonucleotide probes, read out the hybridization pattern to determine sequence.
• §102 posture: These are the archetypal §102(a)/§102(b) SBH art (Drmanac's underlying published work appeared from 1987–1989, i.e., at or before the 1989-06-07 priority). Their filing dates were not verified in this session, so I cannot state their exact §102(e) windows.
• Claims potentially anticipated: any claim reciting only "array of oligonucleotide probes + labeled nucleic acid + hybridization detection." Claims 1 and 4 as described add the two-distinguishable-label and differential-expression elements; on the retrieved description these references do not disclose two-color simultaneous detection, so they are §103 rather than §102 art against 1/4, and §102 art against any bare SBH/array claim.

US 5,002,867 (1991-03-26), Macevicz, "Nucleic acid sequence determination by multiple mixed oligonucleotide probes"

• Disclosure: sequence determination using mixtures/pools of oligonucleotide probes with encoding of pooled positions.
• §102 posture: §102(b) against any claim whose effective date is after 1990-03-26; §102(a) as of 1991-03-26 otherwise. (For claims getting the 1996-06-25 date, everything before 1995-06-25 is §102(b).)
• Claims potentially anticipated: claims reciting detection with multiple mixed probes/pooled probes. Macevicz is the cited reference whose "encoding" concept comes nearest to a multi-label readout; I could not verify whether it discloses two labels distinguishable from one another, which is the element claim 1 turns on. Flagged as unresolved — do not treat as §102 art against claim 1 without the full text.

US 5,143,854 (1992-09-01), Pirrung et al. (filed 1990-03-07 as 07/492,462)

• Disclosure: large-scale photolithographic solid-phase synthesis of a matrix of polymers on a substrate with receptor binding screening — the foundational array-substrate reference.
• §102 posture (important nuance): although Fodor is a common inventor with the '992 patent, this is a §102(b) printed publication as of 1992-09-01 (the patentee's own earlier publication is a statutory bar under §102(b); "by another" is only required for §102(a)/(e)). So it is §102(b) art only for claims whose effective date is after 1991-09-01 — i.e., the two-color/differential-expression matter added in the 1993/1996 lineage, not matter entitled to 1989-06-07 or 1990-03-07.
• Claims potentially anticipated: any claim whose only novelty is "providing an array of different polynucleotides at known locations on a substrate."
• Contradiction flag: this reference is a parent-family document, so it cannot be §102(e) art against the '992 patent; treat any secondary source that lists it as §102(e) art as an error.

Tier 2 — solid-phase hybridization / immobilization

US 5,215,882 (1993-06-01), Bahl et al. — immobilizing nucleic acid on a solid surface for hybridization assays. §102(b) only for claims dated after 1992-06-01; anticipates claims to solid-phase hybridization per se, not the two-label array method.

WO 89/11548 A1 (1989-11-30), "Immobilized sequence-specific probes" — immobilized probe hybridization without electrophoresis. §102(a) art for claims invented after 1989-11-30; §102(b) not available if 1989-06-07 controls.

WO 90/00626 A1 (1990-01-25), "Solid phase assembly and reconstruction of biopolymers" — solid-phase assembly of biopolymers. §102(b) for claims dated after 1990-01-25.

EP 0 392 546 A (1990-10-17) — determining short sequences by hybridization to oligonucleotide probes on discrete microscopic particles. §102(b) for claims dated after 1989-10-17; relevant to any claim reciting particle/bead-based hybridization, but not to a planar fixed-array claim.

GB 2 233 654 A (1991-01-16) — title not retrieved; on its date alone it is §102(b) art for any claim whose effective filing date is after 1990-01-16. I cannot state what it discloses or which claims it might anticipate. Do not rely on this entry.

Tier 3 — labeling, amplification, and fabrication chemistry (narrow claims only)

US 4,965,188 (1990-10-23), Mullis et al. — PCR with a thermostable enzyme. §102(b) against any claim dated after 1989-10-23. Anticipates any dependent claim reciting amplification/labeled amplification of the target nucleic acids; does not touch the array or two-color elements.

US 5,026,840 (1991-06-25), Dattagupta et al. — photochemical nucleic-acid labeling reagent with polyalkylene spacer. §102(b) for claims dated after 1990-06-25; labeling-chemistry claims only.

US 4,855,225 (1989-08-08), Fung et al. — detecting electrophoretically separated oligonucleotides via labeled probes. Published after 1989-06-07, so §102(a) only (and only for claims invented after that date); not §102(b). Relevant to detection/labeling, not to arrays.

US 4,981,783 (1991-01-01), Augenlicht — detecting pathological conditions by nucleic-acid hybridization (gel/blot-based). §102(b) for claims dated after 1990-01-01. Anticipates only claims directed to diagnosing a condition via hybridization of a labeled sample.

US 4,713,326 (1987-12-15) and US 4,542,102 (1985-09-17), Dattagupta et al. — photochemical coupling of nucleic acids to solid supports. Both pre-date even the 1988-06-07 critical date, so both are §102(b) art against every claim in the patent regardless of which priority date controls. They anticipate only claims reciting photochemical immobilization of nucleic acid on a support — a substrate-preparation step, not the detecting method of claims 1/4.

US 4,689,405 (1987-08-25), Frank et al. — simultaneous synthesis of several oligonucleotides on a solid phase (segment/disk format). §102(b) art for all claims (pre-1988). Anticipates claims to making plural oligonucleotides on a solid support.

US 4,728,591 (1988-03-01), Clark et al. — self-assembled nanometer lithographic masks/templates for parallel fabrication. §102(b) art for all claims (1988-03-01 is more than one year before 1989-06-07). Anticipates claims to mask-based parallel patterning for array fabrication; irrelevant to the detection steps.

5. Bottom line on the cited art

1. Most relevant cited prior art overall: the SBH cluster (US 5,202,231; 5,492,806; 5,525,464 — Drmanac) plus WO 89/10977 for the array-hybridization concept, and US 5,143,854 (Pirrung/Fodor) for the substrate-array concept. US 5,002,867 (Macevicz) is the reference worth an immediate full-text pull because its pooled/multi-probe encoding is the only cited document that plausibly approaches the "two distinguishable labels" limitation of claim 1.
2. No cited reference appears to anticipate claims 1 or 4 as those claims are described in the litigation record — each lacks at least the two-distinguishable-label simultaneous detection / differential-expression element. Their practical role is §103 (and §112) art, which is consistent with the fact that the '992 claims fell in litigation on indefiniteness, not anticipation.
3. Three of the 21 cited references are the patent's own family (US 5,143,854; US 5,445,934; and the '992's own lineage) — they cannot be §102(e) art ("by another"); US 5,445,934 in particular (issued 1995-08-29) is not §102(b) art against any of the plausible effective dates and should not be treated as anticipating art.
4. Two references are unusable in this analysis: the truncated "WO 19…" entry (#21) and GB 2 233 654 A (#20, title not retrieved). I am flagging rather than guessing.

6. What I could not verify (stated plainly)

• Verbatim claim text of US 5,800,992 — not retrieved; the authoritative text supplied omits the claims. §102 mapping to claims 1/3/4/5 is based on the Hyseq court's paraphrase.
• Filing dates of the cited US patents (other than US 5,143,854, whose 1990-03-07 filing is confirmed by the family data). This blunts the §102(e) analysis.
• The "Other References"/NPL list on the '992 front page — not retrieved; I have deliberately not substituted known SBH literature (e.g., the 1988–1989 Lysov/Drmanac publications) as if it were cited on the face of this patent.
• The truncated foreign reference (#21) and the subject matter of GB 2 233 654 A (#20).
• Whether US 5,002,867 discloses two distinguishable labels — the pivotal question for claim 1, unresolved.

Next steps if you want this hardened: (a) pull the full text (claims + front page) from USPTO Patent Public Search / PatentCenter for 5,800,992; (b) pull the full text of US 5,002,867 and WO 89/10977; (c) resolve the truncated foreign citation; (d) run the Darts-ip family-litigation record at https://patents.darts-ip.com/?family=27496811 for any inter partes invalidity contentions that name the art actually relied on against claims 1–5.

I'll ground the obviousness analysis in the actual prior-art citations on this patent's record. Let me pull those.

Let me retrieve the complete cited-reference list and any non-patent literature cited.

Obviousness Analysis — U.S. Patent No. 5,800,992 ("Method of detecting nucleic acids")

Analyst note on sourcing. I built this analysis on (a) the patent record as fetched, (b) the examiner/cited prior-art list appearing on the face of the patent via FreePatentsOnline (https://FreePatentsOnline.com/5800992.html), and (c) the Affymetrix v. Hyseq claim/patent description from CourtListener (https://www.courtlistener.com/opinion/[2457323](/patent/2457323)/affymetrix-inc-v-hyseq-inc/). The fetched Google Patents text was truncated before the Claims section, and one search for the non-patent-literature citation list hit a step limit. So the claim element map below is drawn from the CourtListener description of claims 1 and 4, not from verbatim claim text. That is flagged again in the caveats. This builds on, and does not repeat, the litigation section above.

1. Threshold issue that controls the entire §103 analysis: the effective filing date

The Google Patents record lists the priority date as 1989-06-07 (application 07/362,901), with a chain running 1989-06-07 → 1990-03-07 (07/492,462) → 1990-12-06 (07/624,114) → 1993-12-15 (08/168,904) → the 1996-06-25 filing (08/670,118) that issued as the '992 patent. The Hyseq opinion confirms all three sibling patents "derive from the originally filed U.S. Patent Application No. 362,901" via separate CIP chains.

This matters enormously, because a large fraction of the references cited on the face of the '992 patent post-date 1989-06-07:

Consequence: The obviousness case is strong if claims 1–5 are entitled only to the 1990-12-06 (or later) CIP date, in which case Southern's WO 89/10977 (published 1989-11-16, more than a year before) is squarely §102(b) art; Macevicz, Drmanac, Augenlicht, Bahl, and Dower's WO 90/15070 all qualify too. It is substantially weaker if the claims get the 1989-06-07 date, because Southern, Macevicz, Drmanac's WO-family and Dower's publication all fall away and only the pre-June-1989 references survive (US 4,542,102 and 4,713,326 Dattagupta; US 4,689,405 Frank; US 4,728,591 Clark; US 4,855,225 Fung; and possibly the 1989 Southern Genomics paper if it is §102(b) art by publication).

Because the '992's independent claims are directed to the two-label / differential-expression subject matter (claim 1 = simultaneously detecting two sets of sequences with distinguishable labels on an array; claim 4 = differential gene expression between two cell types using distinct fluorescent labels, per the Hyseq opinion), and because that subject matter is the latest material in the CIP chain, a defendant would argue the claims are entitled only to a 1990 or 1993 date. That argument is the single highest-leverage §103 argument available.

2. Element-by-element mapping of the independent claims to the art

The Hyseq opinion describes the claims as follows: claim 1 recites simultaneously detecting two sets of specific nucleic acid sequences, where one collection is labeled with one label and another with a second, distinguishable label, the collections being substantially complementary to nucleic acids of an array, contacting the array to detect hybridization; claim 4 recites differential expression of a plurality of genes in one cell type vs. another, using distinct fluorescent labels examined under fluorescence excitation, under conditions allowing hybridization to complementary sequence polynucleotides in the array.

3. Combinations that render the claims obvious

Combination A — Southern + Augenlicht + Mullis (+ routine dual labeling)

"Array of polynucleotides on a substrate + hybridization detection" = Southern WO 89/10977 (or WO 89/11548).
"Quantitative measurement of gene expression by hybridization, comparing two biological states" = Augenlicht US 4,981,783.
"Preparing labeled target from a sample" = Mullis US 4,965,188 and Dattagupta US 5,026,840.

Motivation: Augenlicht expressly frames hybridization as a quantitative, comparative expression/diagnostic tool; Southern expressly frames a spatially addressed array of oligonucleotides as a platform for parallel hybridization analysis. Both are in the same field, address the same problem (parallel sequence analysis of a complex sample), and the combination yields precisely the claim-1/claim-4 method. Using two spectrally distinguishable fluorophores so that two labeled populations can be read in one hybridization is a routine design choice, and the art recognized distinct fluorescent labels as the detection means of choice (cf. Fung US 4,855,225; Augenlicht). No reference teaches away from multiplexing on an array.

Combination B — Southern/Drmanac/Macevicz + Pirrung '854/Dower WO 90/15070 + Augenlicht

Array platform = Southern WO 89/10977; high-density positionally addressable array fabrication = Pirrung US 5,143,854 + Dower WO 90/15070; expression readout = Augenlicht.

Motivation: Drmanac's and Macevicz's own work was directed at increasing the number of hybridization events readable in parallel, creating an express design incentive to increase array density — which Pirrung/Dower supply. The Federal Circuit/KSR frame applies directly: a finite, small set of identified solutions (immobilize on a support; use photolithographic or spotting/masking methods to position probes; label the target; detect by fluorescence) all lead predictably to the claimed method.

Combination C — Augenlicht + Southern + Pirrung, with PCR-labeled target

The "differential expression of a plurality of genes in two cell types" limitation of claim 4 is the raison d'être of Augenlicht's method; the only change is to run the experiment in the array format of Southern and to label the two populations with two distinct fluorophores. That is a predictable combination of known elements performing their known functions, with the resulting two-color array readout being the expected, not an unexpected, result.

4. Why a POSITA would have combined these references

1. Same field, same problem. Southern, Drmanac, Macevicz, and Augenlicht all concern detecting/quantifying specific nucleic acid sequences from complex samples by hybridization. The problem the '992 claims solve — reading, in one experiment, the relative abundance of many sequences — is the direct objective of Augenlicht (comparative expression) plus Southern/Drmanac (addressability and parallelism).
2. Explicit, enumerated alternative approaches. The cited art already recites the finite set of options: arrays made by masking/pen-plotter (Southern), simultaneous solid-phase synthesis (Frank), photolithographic synthesis (Pirrung/Dower), and support-bound oligonucleotides (WO 90/03382). Under KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007), combining known options in this finite, predictable space is obvious.
3. Dual-label detection was routine. Two distinguishable labels read in the same experiment is standard molecular-biology practice; the patent itself does not assert any unexpected property of the two-color format, only a fluorescent-label preference (see uspto.report characterization: "a fluorescent label is probably most convenient… other sorts of labels, e.g., radioactive, enzyme linked, optically detectable, or spectroscopic labels may be used," https://uspto.report/patent/grant/5800992).
4. Historical confirmation that the combination was being made contemporaneously. Southern's own array patent was granted in Europe in 1989 and covered "the technique of using oligonucleotide arrays as a testing platform"; by 1997 the field was in open conflict over DNA-chip rights, with Affymetrix itself attacking the Southern claims as "not novel, not inventive" (Nature, "Truce likely in battle over 'DNA-chip' patent rights," https://www.nature.com/articles/387221b0.pdf). The dense, overlapping filings by Southern, Drmanac, Macevicz, Fodor/Pirrung and Dower, all within 1989–1991, is itself evidence that the array-plus-hybridization combination was the obvious next step rather than an inventive leap.
5. No teaching away. None of the cited references criticizes the combination; the only "teaching away" of record relates to probe-array limitations (e.g., the acknowledged "inability to distinguish single-base changes at all positions," discussed in US 6,852,487), which is a limitation on specificity, not on the two-color array concept.

5. Claim-by-claim conclusions (with confidence levels)

6. Secondary considerations and counterweights (be candid about these)

• The patent survived the litigation only by settlement. Affymetrix lost the key merits rulings in the Incyte/Synteni action — including the May 8, 2001 holding that "substantially complementary" was indefinite, invalidating the '992 claims using that term — and the parties settled everything on December 21, 2001 before any appellate review. There is no Federal Circuit §103 holding on the '992 patent to rely on either way. (See the Incyte disclosures and press release cited in the litigation section above.)
• Objective evidence of non-obviousness would be the patentee's best counter: long-felt need, industry skepticism, commercial success of Affymetrix GeneChips, and the very fact that major competitors (Hyseq, Incyte, Oxford Gene Technology) contested the space. A Gillman/Graham factor-2 record (nexus between the commercial product and the claimed two-color array method) would need to be built from Affymetrix's own product and licensing evidence — I have not verified a nexus record, so I flag this as unproven.
• The §112 issue is not a §103 issue, but it matters practically: a claim held indefinite cannot be infringed and may be invalid on that separate ground, which reduces the value of a pure §103 attack and may make the priority-date argument moot as a matter of litigation strategy.

7. What I could not verify (do not treat as established)

1. Verbatim claim 1–5 text. The fetched patent page was truncated before the Claims; my element map rests on the CourtListener/Hyseq paraphrase. Before filing any obviousness contention, pull the claims from the USPTO PatentCenter or the granted patent PDF (https://patents.google.com/patent/[US5800992](/patent/US5800992)/en, USPTO link).
2. The non-patent-literature citation list (e.g., Fodor et al., Science 1991; Maskos & Southern, NAR 1992; Drmanac et al., Genomics 1989; Khrapko et al., 1989; Saiki et al., 1985). These are the references most likely to supply the two-label/differential-expression teaching, and my search for them hit a step limit. This is the most important gap in the analysis — several of these NPL items are dated 1989–1992 and therefore also hinge on the priority-date issue.
3. The effective filing date of claims 1–5 — I flag the two scenarios but cannot resolve which controls without the prosecution history (the §112 written-description support for the two-color/differential-expression limitations).
4. Whether WO 90/15070 was among the references the examiner relied on or merely a family citation — Google Patents' classification of "cited/considered" vs. "background" references was not retrievable from the truncated text.

Recommended next steps: (a) obtain the granted claims and the file wrapper for 08/670,118 and its CIP parents 07/624,114 and 08/168,904; (b) retrieve the full NPL citation list from the patent PDF; (c) confirm the publication dates of WO 89/10977 and WO 90/15070 against the established effective date to fix the statutory category of each reference (§102(a) vs. §102(b) vs. §102(e)); and (d) build the secondary-considerations record from Affymetrix's GeneChip commercial and licensing history if a validity challenge is contemplated.